Multicenter evaluation of a fluorometric enzyme immunocapture assay to detect Toxoplasma-specific immunoglobulin M in dried blood filter paper specimens from newborns

An easy-to-perform fluorometric enzyme immunocapture assay (FEIA) was developed by Labsystems, HeI-sinki, Finland, to detect toxoplasma-specific immunoglobulin M (IgM) in dried blood spots, Assay materials were distributed to two sites that have programs in place designed to identify infants born with congenital toxoplasma infection: the Statens Serum Institut, Copenhagen, Denmark, and the New England Regional Newborn Screening Program, Boston, Mass, Each site tested over 700 dried blood samples from healthy newborns to define a cutoff at the 99.5 percentile (5 enzyme immunounits for Copenhagen and 4 enzyme immunounits for Boston), Each site then applied its own cutoff to interpret results for dried blood spots prepared from either adults with serology suggestive of acute infection (Copenhagen) or infants determined to be congenitally infected on the basis of serological criteria (Boston), In Copenhagen, 35 of 38 adult samples were positive by FEIA; the remaining 3 were also negative by immunosorbent agglutination assay for IgM and were either positive to a small degree or borderline positive for IgA, These samples thus may not represent acute infection, In Boston, of 26 congenitally infected infants, 22 were positive by FEIA, The four infant specimens not positive by FEIA were either negative or borderline positive by the standard Boston assay, These results demonstrate that the IgM FEIA is a potential alternative to other filter paper assays for toxoplasma-specific IgM currently in use for newborns.